By Sam Boughedda Johnson & Johnson's (NYSE:JNJ) share price has plunged after a report by The Wall Street Journal stated that the company's talc unit wasn't in financial distress. As a...
- Day's Range
- 161.42 - 163.88
- 52 wk Range
- 155.72 - 186.69
- Prev. Close
- Average Vol.(3m)
- 1-Year Change
- Market Cap
- P/E Ratio
- United States
- Shares Outstanding
- Dividend (Yield)
- 4.52 (2.77%)
- Next Earnings Date
- Apr 18, 2023
By Geoffrey Smith Investing.com -- Stocks in focus in premarket trading. Please refresh for updates. 3M (NYSE:MMM) stock fell 4.5% after the company missed its forecasts for the fourth...
By Investing.com Staff Shares of Johnson & Johnson (NYSE:JNJ) rose in pre-open trading Tuesday after the pharmaceutical giant reported better-than-expected fourth quarter...
Johnson & Johnson (JNJ) reported Q4 EPS of $2.35, $0.11 better than the analyst estimate of $2.24. Revenue for the quarter came in at $23.7 billion versus the consensus estimate of $23.9...
Investing.com - J&J (NYSE: JNJ) reported fourth quarter EPS of $2.35, $0.11 better than the analyst estimate of $2.24. Revenue for the quarter came in at $23.7B versus the consensus...
By Oliver Gray Investing.com - U.S. stock futures were little changed during Monday’s evening trade after major indices finished the regular session higher as investors digested a fresh...
By Senad Karaahmetovic Shares of Fate Therapeutics (NASDAQ:FATE) are down more than 56% in pre-market after the company said it has declined a proposal from Janssen Biotech, which is owned...
By Daniel Shvartsman Investing.com -- Entering the last trading day of the year, it's no surprise to find the 2022 scoreboard filled with energy winners and tech losers.The Dow Jones...
By Scott Kanowsky Investing.com -- Amgen Inc. (NASDAQ:AMGN) has agreed to buy Horizon Therapeutics PLC (NASDAQ:HZNP) in an all-cash deal that values the biotech firm at about $28.3 billion,...
By Geoffrey Smith Invesitng.com -- Central bank meetings are set to dominate the week, with the Federal Reserve, European Central Bank, and Bank of England, all expected to raise their key...
By Senad Karaahmetovic Amgen (NASDAQ:AMGN) has agreed to acquire Horizon Therapeutics (NASDAQ:HZNP), according to Bloomberg News. Amgen agreed to pay $116.5 for each HZNP share, valuing the...
By Scott Kanowsky Investing.com -- Shares in Sanofi SA (EPA:SASY) rose on Monday after the French drugmaker backed out of its plans to bid for biotech company Horizon Therapeutics PLC...
By Investing.com Staff After five days of selling pressure, stocks finally snapped the streak today following a rise in jobless claims. Amid the upside, several rumors swirled around Wall...
By Investing.com Staff Stocks were heavy Monday as positive economic data stirred concerns the Fed will have to maintain its hawkishness on rates. Amid the downside, several rumors swirled...
By Investing.com Staff Horizon Therapeutics (NASDAQ:HZNP) fell nearly 5% in early trading Monday after it was disclosed that one of the three original bidders for the company dropped...
By Laura Sánchez Investing.com -- Danelfin has released its new December ranking of the stocks most likely to beat the market. Until now, the monthly rankings were based solely on the AI...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.